| Clinical Efficacy of Combination Chemotherapy with Ifosfamide Cisplatin, and Etoposide(ICE) in Advanced Non-Small Cell Lung Cancer. |
|
Gu Lee, Byung Duk Kim, Hee Jung Kang, Sang Won Lee, Hyun A Oh, Sung Hwa Bae, Jae Lyun Lee, Kyung Hee Lee, Myung Soo Hyun, Kyeong Cheol Shin, Jin Hong Jung, Kwan Ho Lee, Hun Mo Ryu |
1Department of Internal Medicine, College of Medicine, Yeungnam University, Korea. impride@dreamwiz.com
2Department of Internal Medicine, College of Medicine, Catholic University of Daegu, Daegu, Korea. |
|
|
| Abstract |
BACKGROUND
To evaluate the efficacy and toxicity of combination chemotherapy using ifosfamide, cisplatin, and etoposide in patients with advanced non-small cell lung cancer(NSCLC). MATERIALS AND METHODS: Thirty-three patients with inoperable NSCLC(stage III b+IV) who had measurable diseases, and had not been treated with chemotherapeutic drugs, were enrolled in this study(from March 1995 to December 1996). The patients received ifosfamide(1500mg/m2/day, a full drop with Mesna on days 1-5), Cisplatin (80mg/m2/day infusion with a hydration on day 2), and Etoposide (100mg/m2/day infusion for 2 hours on days 1-3). The treatment was repeated every 4 weeks. RESULTS: Ten patients showed a partial responses (30.3%). The overall survival time of the responders was longer than that of the non-responders (median 55 vs 22 weeks, p=0.01). The toxicities of this treatment were tolerable. Grade 3 or 4 leukopenia was observed in 21%. There was 1 death related to febrile neutropenia. The non-hematologic toxicity was mild. The relative dose intensity given to the patients was 0.86 ifosfamide, 0.87 cisplatin, and 0.89 etoposide, showing an average dose intensity of 0.87. CONCLUSIONS: A combination regimen of ifosfamide, cisplatin, and etoposide is effective and tolerable for treating advanced non-small cell lung cancer. |
| Key Words:
Ifosfamide, Cisplatin, Etoposide, g Non-small-cell lung cancer, Chemotherapy |
|
PDF Links
Full text via DOI
Download Citation
